XNASINAB
Market cap22mUSD
Jan 14, Last price
0.32USD
1D
-0.16%
1Q
38.27%
IPO
-96.84%
Name
IN8BIO, Inc.
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
37.07%
Rev. gr., 5y
%
Revenues
0k
Net income
-30m
L+9.44%
CFO
-23m
L-3.24%
Profile
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 32,838 | 29,624 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (32,838) | (29,624) | ||||
NOPBT Margin | ||||||
Operating Taxes | (1,103) | |||||
Tax Rate | ||||||
NOPAT | (32,838) | (28,521) | ||||
Net income | (30,007) 9.44% | (27,418) 87.12% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 24,564 | 9,542 | ||||
BB yield | -59.60% | -19.70% | ||||
| Debt | ||||||
Debt current | 3,028 | 1,389 | ||||
Long-term debt | 8,272 | 10,359 | ||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (9,982) | (6,686) | ||||
| Cash flow | ||||||
Cash from operating activities | (23,340) | (24,121) | ||||
CAPEX | (600) | (3,705) | ||||
Cash from investing activities | (600) | (3,705) | ||||
Cash from financing activities | 27,044 | 8,988 | ||||
FCF | (32,091) | (35,656) | ||||
| Balance | ||||||
Cash | 21,282 | 18,182 | ||||
Long term investments | 252 | |||||
Excess cash | 21,282 | 18,434 | ||||
Stockholders' equity | (91,215) | (61,209) | ||||
Invested Capital | 122,559 | 89,815 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 29,865 | 20,968 | ||||
Price | 1.38 -40.26% | 2.31 -47.38% | ||||
Market cap | 41,214 -14.91% | 48,436 -41.25% | ||||
EV | 31,232 | 41,750 | ||||
EBITDA | (30,337) | (28,521) | ||||
EV/EBITDA | ||||||
Interest | 1,103 | |||||
Interest/NOPBT | ||||||